Acuta Capital Partners’s Ventyx Biosciences VTYX Stock Holding History

Acuta Capital Partners’s Portfolio VTYX Stock Details VTYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-205,377	Closed	-$7.13M	–	57
2023 Q3	$7.13M	Buy	205,377 +58,059	+39%	+$2.01M	4.78%	8
2023 Q2	$4.83M	Sell	147,318 -61,182	-29%	-$2.11M	3.27%	13
2023 Q1	$6.98M	Sell	208,500 -82,000	-28%	-$3.19M	5.15%	5
2022 Q4	$7.56M	Buy	290,500 +110,500	+61%	+$3.27M	4.65%	9
2022 Q3	$6.28M	Buy	180,000 +58,000	+48%	+$1.28M	2.71%	14
2022 Q2	$1.49M	Buy	122,000 +51,123	+72%	+$764K	0.83%	31
2022 Q1	$962K	Buy	+70,877	New	+$947K	0.45%	34

Other funds holding VTYX

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Acuta Capital Partners's VTYX Position: Q4 2023 in Review

Acuta Capital Partners sold out of Ventyx Biosciences (VTYX) in Q4 2023, closing a stake of 205,377 shares — an estimated $7.13M sold.

Acuta Capital Partners first reported a position in VTYX in Q1 2022 and held it in 7 quarters. The position peaked at $7.56M in Q4 2022. 121 funds tracked by Wall St. Rank hold VTYX as of Q4 2023.

Acuta Capital Partners reported no remaining Ventyx Biosciences position as of Q4 2023 after selling out during the quarter.
Acuta Capital Partners sold 205,377 Ventyx Biosciences shares in Q4 2023, an estimated $7.13M.
Acuta Capital Partners first reported a position in Ventyx Biosciences in Q1 2022 and held it in 7 quarters.
Acuta Capital Partners's Ventyx Biosciences position peaked at $7.56M in Q4 2022.
121 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q4 2023.

Based on Acuta Capital Partners's 13F filing for Q4 2023, filed 14 Feb 2024.